ExoXpert, a CDMO specializing in exosome production and a subsidiary of Exo Biologics, entered a strategic partnership with Neucore Bio, a next-generation, non-viral engineered delivery technology company to leverage ExoXpert’s platform for evaluation of advanced exosome loading.
 
Under the agreement, ExoXpert will leverage its ExoPulse platform to test and optimize efficient loading of proprietary payloads into exosomes as part of Neucore’s Fibroblast EV Engineering (FiXE) discovery platform. ExoPulse is ExoXpert’s latest exosome-based therapeutic platform, currently used in clinical trials. It has been specifically designed to facilitate the production and loading of exosomes. 
 
This partnership aims to enable greater clarity on maximizing the therapeutic effect of Neucore’s FiXE platform as it advances clinical development.
 
“This collaboration is an important step in the loading validation and application of our FiXE platform using advanced, non-viral exosomes for therapeutic delivery,” said Kenneth Morand, PhD, CEO, Neucore Bio. “We believe ExoXpert’s demonstrated exosome experience with its ExoPulse platform will enable a highly efficient and collaborative process to answer this critical question in our scientific strategy.” 
 
“EXO Biologics recently created ExoXpert as an exosome CDMO to meet the demand for specialized GMP grade exosome manufacturing services internationally. As a therapeutic exosome developer, this was something EXO Biologics needed, but we also realized the international market needed this as well,” said Hugues Wallemacq, CEO,  ExoXpert and EXO Biologics. “ExoXpert has started working with a significant number of international cell and gene therapy developers that need a combination of exosome manufacturing and knowledge to develop new products for the benefit of patients. Partnering with Neucore will enable ExoXpert to further extend ExoXpert’s expertise in loading exosomes to Neucore’s FiXE platform.”